Board and auditor

The Board currently consists of five (5) members without deputies. All board members are independent in relation to the main owner, and independent in relation to the company and the company management.

Henrik Rammer

Chairman of the board

Born 1974. Chairman of the Board since November 2014.

From November 2014, Henrik Rammer has been Chairman of the Board for all companies within Chordate. Henrik has many years of experience within private equity and worked for Axcel Management AB during the period 2008-2013 and for Triton Advisers (Sweden) AB from 2002 to 2007. Henrik currently works as a private investor at a number of different companies. BSc. degree from the London School of Economics, acquired in 1996.

Shares: 6,664,798
Warrants: 350,000

Otto Skolling

Vice Chairman of the board

Born 1961. Vice Chairman of the Board since May 2023

Otto Skolling has over 30 years of experience in product development, business development and project management within the pharmaceutical and medical technology industry, and has previously held leading positions at, among others, Novozymes, Siemens Life Support Systems and Pharmacia & Upjohn. Currently, Otto is Director Business Development at Nanexa, Chief Business Officer at Asarina Pharma AB, board member at Respinor AS and Lipidor AB, as well as CEO and chairman of the board at Pharmor AB. Otto has a MSc in chemical engineering from KTH Royal Institute of Technology in Stockholm.

Shares: 0
Warrants: 350,000

Tommy Hedberg

Board member

Born 1955. Board member since June 2014.

Tommy Hedberg currently sits on the Boards of a number of different companies in Sweden. Tommy was CEO during the period 1998-2014 and before that was Head of Sales and Marketing at Atos Medical from 1990. Previously Head of Sales and Marketing at Medscand AB and Janssen Pharma AB. Studied chemical engineering followed by a post-secondary university education in economics, acquired in 1976.

Shares (and through related parties): 12,399,852
Warrants: 225,000

Gunilla Lundmark

Gunilla Lundmark

Board member

Born 1963. Board member since April 2017.

Gunilla is CEO for Uppsala University’s holding company UU Invest, and was previously CEO of Pharmanest AB. Gunilla has over 25 years of experience from different leading managerial posts within the pharmaceuticals and medical technology industries, including Deputy CEO at Q-Med AB. Gunilla holds an Executive MBA from Uppsala University, acquired in 1999, and a BSc. in Biomedicine from Uppsala University, acquired in 1985.

Shares: 0
Warrants: 350,000

Caroline Lundgren Brandberg

Board member

Born 1979. Board member since October 2021.

Caroline is currently the Global Sales Director at climate tech company Deedster and has previously worked within Ericsson, among others, in various leading roles with a focus on sales and marketing. She also has several board assignments, including at Stockholm University. Caroline is originally a civil engineer specialized in technical physics with a Master of Science from Uppsala University, acquired in 2005, and an Executive MBA from Stockholm University, acquired in 2017.

Shares (and through related parties): 7,420,271
Warrants: 225,000

Henrik Boman


Öhrlings PricewaterhouseCoopers with authorized public accountant Henrik Boman as principal auditor.

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the treatment Ozilia™, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia™ in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact